Visceral leishmaniasis (VL) is life-threatening parasitic disease which is responsible for the death of 50,000 patients/year. Sodiumstibogluconate/paromomycin combined drugs are recommended to treat VL in East Africa. However, the adverse effect of those drugs is not studied in the study area. Therefore, the aim of the study was to assess serum amylase, lipase and associated factors among patients with these VL drugs. Cross-sectional study was conducted at the Universty of Gondar Comprehensive Specialized Hospital Kala-azar Research and Treatment Center from February-September 2020 G.C. Descriptive data was presented by tables, charts and graphs. Data was entered by EpiData 3.1 then exported to STATA 14.1 SE, for analysis, paired t-test was used, for factors correlation and multivariate regression was used. The mean SD level of serum amylase and lipase at TOC showed a statistically significant elevation (P